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Abstract
The Melanoma Research Foundation (MRF) has charted a comprehensive assessment of the 
current state of melanoma research and care. Intensive discussions among members of the MRF 
Scientific Advisory Council and Breakthrough Consortium, a group that included clinicians and 
scientists, focused on four thematic areas—diagnosis/early detection, prevention, tumor cell 
dormancy (including metastasis) and therapy (response and resistance). These discussions 
extended over the course of 2015 and culminated at the Society of Melanoma Research 2015 
International Congress in November. Each of the four groups has outlined their thoughts per the 
current status, challenges and opportunities in the four respective areas. The current state and 
immediate and long-term needs of the melanoma field, from basic research to clinical 
management, are presented in the following report.
Prologue
The field of melanoma—both research and clinical management—has exponentially 
expanded over the past decade and has become a paradigm for understanding cancer 
signaling, tumor immunology and their clinical application. Recognizing how rewired 
signaling underlies melanoma progression has prompted development of specific drugs 
(such as vemurafenib and dabrafenib) that decrease tumor burden, although only for a 
limited time period. Combination drug therapy has also emerged as a way to provide a more 
sustainable response, raising critical questions relevant to which combination(s) are most 
effective. In addition, the discovery of processes underlying melanomagenesis, and on 
mechanisms that underlie the traditional immune suppressive features of advanced 
melanomas has led to radical progress in devising and applying immune checkpoint 
therapies. Advances made with melanoma are now being productively applied to other forms 
of cancer. Yet, despite all of these advances, fundamental questions pertaining to prevention, 
detection, diagnosis, tumor progression (including dormancy and metastasis) and response 
to therapy (including resistance) remain: Can we develop better tools to detect melanoma 
earlier? Will identification of melanoma subtypes dictate therapy? What causes melanoma 
cells to remain dormant for years and then re-awaken? How does resistance to therapy and 
metastatic propensity arise so readily, and how does tumor heterogeneity confound efforts to 
achieve durable responses? Can better tools be developed to prevent and detect metastasis? 
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What should be the mode and sequence of therapy administration when combinations are 
used? How do we prioritize the development of immunotherapy-based combinations? How 
do we select patients for single agent versus combination immunotherapy? What are the 
mechanisms of resistance to immunotherapy? These questions are of concern to clinicians 
and basic researchers alike, and many are addressed in the following report.
Prevention
Melanoma arises through progressive accumulation of genetic and (epi)genetic alterations 
that disrupt homeostatic pathways, resulting in uncontrolled tumor cell proliferation 
followed by invasion and lymphatic or hematogenous dissemination of the tumor cells to 
distant sites. In cutaneous melanocytic neoplasms, UV radiation is the primary cause of 
mutations on sun-exposed skin. Therefore, an individual’s susceptibility to melanoma is 
likely determined by genetic and epigenetic factors that determine the rate at which 
mutations are generated and fixed (e.g. the intrinsic ability of melanocytic cells to mount 
shielding responses to UV radiation, for example, by inducing tanning). DNA repair 
capacity, as well as environmental factors, mainly dose and timing of UV exposure during 
early periods of life, also dictates risk factors for malignant transformation.
The precise role of UV radiation in carcinogenesis still requires greater understanding, such 
as the relative contributions of UVA versus UVB wavelengths. This would be of enormous 
importance, given the ongoing efforts to devise broad-spectrum sunscreen agents approved 
by the FDA. There is strong evidence for UV-independent mutagenesis in melanoma, a 
possibility suggested by the occurrence of melanomas at cutaneous locations that are not sun 
exposed, as well as in the eye and in mucous membranes. Analysis of animal models also 
shows that melanin, in particular pheomelanin, the predominant pigment present in red-
haired/light-skinned individuals, can harbor carcinogenic activity. These observations 
suggest that the relative degree and type of pigmentation is key in determining melanoma 
susceptibility. Research of mechanisms that explain the nature of these carcinogenic 
activities is important and could reveal strategies to neutralize them in the presence or 
absence of UV irradiation.
Previous studies established a positive correlation between melanoma development and traits 
such as light eye and hair color, freckling and nevus density when assessing overall 
melanoma risk, but did not consider risk for specific melanoma subtypes. There is increasing 
evidence that two major types of melanomas can be distinguished on sun-exposed skin. One 
shows macro- and microscopic signs of long-term UV exposure and is specifically 
highlighted by the presence of solar elastosis, a distinctive change in elastic fibers of the 
skin. These melanomas with chronic sun-induced damage (CSD) typically originate on the 
head, neck, and the dorsal surfaces of the distal extremities of older individuals (>55 years 
of age). They also have a high mutation burden and often harbor mutations in NF1, NRAS, 
BRAFnon-V600E, or KIT. The other major type (termed ‘non-CSD melanomas’) typically 
affects intermittently sun-exposed areas such as the trunk and proximal extremities of 
younger individuals (<55 years of age), and patients do not show marked solar elastosis. In 
these cases, tumor cells exhibit a moderate mutation burden and a predominance of 
BRAFV600E mutations. Both types are associated with distinct precursor lesions, ‘non-CSD’ 
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with acquired nevi that already exhibit BRAFV600E mutations and ‘CSD’ with atypical 
melanocytic neoplasms and melanoma in situ.
Prevention strategies
The effectiveness of UV-absorbing sunscreens in melanoma prevention represents an area of 
active investigation and offers significant promise for large populations at risk. Studies 
demonstrate the benefit of sunscreen in melanoma prevention, with up to 50% reduction in 
incidences. Determining whether additional UV protection could result from improved 
sunscreens or their contents [i.e. their ability to reduce the formation of reactive oxygen 
species (ROS)] is of importance.
Prevention strategies should be implemented with the consideration of personal behavior, 
which is affected by our awareness, education, and interaction with the environment (degree 
of exposure to sun or indoor tanning).
Knowing why individuals engage in melanoma risk-associated UV exposure behaviors is 
key to devising methods to improve primary intervention. Work in this area has found that 
tanning is motivated by psychological factors and can be associated with addictive behavior. 
A Comprehensive Indoor Tanning Expectations (CITE) scale found that two positive factors 
(mood enhancement and social approval) and one negative factor (psychological/physical 
discomfort) predicted future indoor tanning behavior among young women in the 
southeastern United States. Additional work is necessary to develop working models to 
understand motivations for melanoma risk-related behaviors across populations. This work 
then needs to be translated into messages and interventions that address the motivators. It 
hardly needs to be stated, but banning the use of tanning salons by minors is a 
straightforward cost-effective mechanism for reducing exposure, and should be a priority for 
every advocacy organization.
Biological addiction in melanoma risk and prevention
Data from human epidemiologic studies demonstrated the presence of true addictive 
behaviors following UV irradiation. These studies suggest that frequent use of tanning beds 
may be associated with “self-treatment” of depressive symptoms and also may satisfy 
psychiatric DSM (Diagnostic and Statistical Manual for mental disorders) criteria for 
addictive human behaviors. Animal models have demonstrated induction of beta-endorphin 
by sun exposure. Collectively, sun-seeking behaviors may represent an evolutionarily 
selected, hardwired pathway; if so, novel approaches are needed to overcome them.
Empowering behavioral change
Empowering behavioral change is essential to translate prevention knowledge into 
meaningful action for populations at risk for melanoma. Compliance with melanoma 
prevention recommendations improves when individuals from hereditary melanoma families 
are provided with personal genetic test results. Individuals with a personal history of 
melanoma are most compliant with prevention recommendations. In addition, informing 
individuals without a personal history of disease that they are carriers of a CDKN2A/p16 
mutation leads to improvement of photoprotection, self-skin examination and professional 
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examination behaviors, in the absence of melanoma diagnosis. Provision of negative genetic 
test results to non-carriers also improved compliance with some but not all medical 
recommendations.
Behavior / risk assessment recommendation—By understanding cognitive 
processes underlying sun exposure behaviors, we may be able to improve communication of 
risk and empower individuals to comply with prevention recommendations (Table 1).
Approaches for melanoma prevention
Increased understanding of pigment cell biology and molecular mechanisms has enhanced 
the potential of employing a preventive approach. This approach targets individuals at risk of 
the disease and uses safe drugs or natural products that may prevent or reverse melanoma 
development. Specific features of melanoma biology, pathogenesis, and epidemiology make 
it an ideal model for chemoprevention approaches, including: identification of key targetable 
signaling pathways, the availability of surrogate disease markers (e.g. dysplastic nevi), the 
accessibility of skin to perform serial non- to minimally-invasive assessments, and 
identification of individuals at risk of developing cutaneous melanoma. Challenges, 
however, remain to be addressed, including: (i) the need to identify drugs with a well-
characterized mechanism of action to prevent melanoma, (ii) analyses of drugs already 
evaluated in humans that rely on validated biomarkers of response as part of future 
intervention studies, and (iii) identification of targeted risk cohorts based on understanding 
of drug mechanism and calculating the risk/benefit ratio of the intervention.
Oxidants/pro-oxidants, vitamin D and eumelanin are among examples of chemicals / natural 
products that have been assessed for their possible effect on melanoma prevention. Those 
include: (i) NSAIDS (non-steroidal anti-inflammatory drugs): Multiple epidemiological 
studies have evaluated the role of NSAIDs in melanoma prevention with controversial 
results. Further studies are thus required to clarify short and long-term effect of NSAIDs and 
their metabolites on melanocytes and melanoma development. (ii) Statins: Meta-analyses 
and intervention clinical trials (using clinical and histological endpoints in benign nevi) do 
not currently support the use of lipid-lowering agents in melanoma chemoprevention. (iii) 
Sulforaphane: Experimental studies indicate that sulforaphane upregulates antioxidant genes 
and may affect immune pathways. Further assessment of its possible use is currently 
underway. (iv) Vitamin D: Several studies point to a possible role of vitamin D 
supplementation as a preventative agent in vitamin D-deficient patients. However, the 
complex relationship between vitamin D and melanoma risk/outcome (higher UV exposure 
results in higher serum vitamin D levels but also higher risk of skin cancer) is recognized 
and need to be considered in these evaluations. A 7-year follow-up trial evaluating the 
effects of calcium and vitamin D supplementation did not reveal a difference in incidence of 
non-melanoma skin cancer or melanoma rates (except in a sub-cohort of patients with a 
history of non-melanoma skin cancer). Further studies that take into consideration sun 
exposure and standardization of molecular markers of response are needed. (v) Antioxidants: 
The effect of systemic antioxidants as melanoma chemoprevention drugs remains 
controversial. A growing body of data suggests that antioxidants, including selenium, may 
promote rather than prevent cancer, an outcome supported by data from large, randomized 
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controlled trials testing selenium and vitamin E in non-melanoma cancers. Interestingly, 
both mouse models of melanoma and xenografts of human melanoma in mice show that 
relief from oxidative stress by treatment with the antioxidant N-acetyl cysteine leads to 
disease progression, suggesting that these approaches be reassessed in carefully crafted 
human and animal-model based studies.
Overall the current chemoprevention data suggests that (i) there is no clear evidence to 
support any particular agent for widespread use in melanoma prevention solution; (ii) in the 
case of antioxidants recent evidence suggests, promotion, rather than prevention of 
melanoma metastasis in certain experimental settings
Emerging opportunities / considerations
Pigmentation modifiers—The use of small molecules to induce the synthesis of 
eumelanin in skin as a means of protecting against skin damage has been proposed and 
carried out via topical administration of the drug forskolin to mice genetically engineered to 
be red-haired and light-skinned. This strategy seeks to mimic inherent protection against 
cutaneous melanoma incidence seen in humans with dark skin pigmentation. The approach 
was found to offer mutant mice significant protection against UV-induced mutagenesis and 
skin carcinogenesis, although it was tested in a squamous cell carcinoma model. Human 
trials have been performed using alpha melanocyte stimulating hormone and active peptides 
derived from MSH that similarly lead to darkening the skin. These agents may have 
substantial off-target effects, including promotion of growth of nevi, which will need to be 
considered in the design of subsequent trials. Approaches to identify safe agents capable of 
modulating eumelanin synthesis in human skin could provide tools to prevent both 
melanoma and non-melanoma skin cancers and serve as a more general cutaneous 
photoprotection method in various contexts (Table 1).
Microbiome considerations—A patient’s microbiome may also play a key role in 
melanoma development and response to therapy. Currently, researchers are asking whether a 
specific subspecies of gut bacteria is associated with resistance to melanoma development 
and whether the presence of select bacterial species correlates with improved therapeutic 
outcomes. Though these initial studies demonstrating the impact of the microbiome on 
cancer therapy (including melanoma) are encouraging, they need to be validated and 
extended to higher resolution (for example, understanding the mechanisms linking the gut 
microbiome with immune responses). Notably, while the gap between mouse and human 
microbiota is recognized, substantial efforts are needed before one may project the mouse-
based studies to human settings. The complexity lies not only in the number of bacterial 
strains, but equally important, in the relationship among them (one bacterial community 
affecting another). Further studies are required to map different bacterial communities in the 
gut and assess their effect on the immune response and the tumor microenvironment. 
Altering the bacterial landscape in a manner that would antagonize tumor development or 
favor therapy, possibly via use of probiotics, is a challenge that would deserves proper 
recognition and attention by the scientific and medical communities at large (Table 1).
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Chemoprevention Recommendations: There is a clear need to perform additional studies 
that incorporate genetic and epigenetic data, dietary, behavior, and sun exposure data 
collection in their design (Table 1). Adequately powered prospective, randomized trials are 
required to assess the implication of regular use of such chemicals. Prior to initiating clinical 
studies, it will be critical to establish the effective dose and timing of the drug, the optimal 
delivery method, which biomarkers are best surrogates of efficacy, and which population of 
patients should be included or excluded. Critical considerations of these studies should be 
the impact of the tested chemical on skin cancer (basal and squamous cell carcinomas) 
versus melanoma, and potentially harmful off-target effects. Such studies will require large, 
risk-selected cohorts and proper stratification across the various arms of prevention studies 
to determine efficacy. It is expected that such an investment could reduce the overall burden 
of the disease and minimize the number of individuals in need of treatment.
Detection/ Early Diagnosis
Melanoma consists of several disease subtypes that differ in their epidemiology, clinical 
manifestation, pathogenesis and clinical course. On sun-exposed skin at least two different 
pathways are distinguished, and other subtypes with distinct features arise from the 
choroidal tract of the eye and meningea, as well as from glabrous (non-hair-bearing skin) 
and mucosa. Additional work is required to precisely delineate these subtypes, define their 
individual predispostion to environmental factors (such as UV exposure), and their 
respective molecular evolution from precursor lesions. A deeper understanding of the 
different pathways for melanoma formation and clearer definitions of melanoma subtypes 
could improve risk prediction and prognostication.
As melanoma screenings efforts continue to expand, it is critical to improve diagnostic 
accuracy of both clinical and histopathological criteria to minimize the risk of harm related 
to screening methods. Histopathological diagnosis remains the gold standard but has proven 
limitations, highlighting the need for identification of additional markers that can assist in 
diagnosis. Several studies show sizeable disagreement among pathologists regarding the 
diagnosis of melanoma and benign melanocytic nevi, with one study reporting up to 15% 
discordance. Thus, it is imperative to improve diagnostic accuracy to decrease false positives 
that might result in unnecessary surgery, adjuvant therapy, and psychological harm. It is even 
more critical to reduce the proportion of false negative diagnoses that could increase 
morbidity and overall survival. Current work that addresses discrimination of melanoma 
from benign or low-grade dyplastic nevi is based on gene expression or DNA copy number 
changes by comprehensive genomic hybridization (CGH) or fluorescence in situ 
hybridization (FISH), while gene expression profiling (GEP) based analyses is gaining 
traction.
It is expected that established melanoma risk phenotypes and genotypes will differ among 
melanoma subtypes. For example, high mole density is positively associated with non-CSD 
melanoma, whereas actinic keratosis and solar lentigines are positively associated with CSD 
melanoma. The same holds for genetic variants, which are likely to reveal similar differences 
between the subtypes. While the precise definitions of these subtypes are still emerging, 
sufficient phenotype and genotype stratification markers are now available to allow studies 
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to assess associated risk. Such studies could help refine criteria to identify individuals at 
high risk for either CSD or non-CSD subtypes and to improve disease education for patients 
and healthcare providers.
A similar rationale applies to early recognition of tumors or high-risk precursor lesions and 
staging criteria for established melanomas. The current ABCDE (A- asymmetry; B- border 
irregularity; C- color variation; D- diameter > 6mm; E – evolving lesions) diagnostic criteria 
could be improved by tailoring them to different subtypes and risk groups. Moreover, AJCC 
(American Joint Committee on Cancer) staging criteria, which are also currently in use, may 
provide improved prognostic information once different criteria or cutoffs for different 
subtypes are developed.
Diagnosis recommendation
(i) While some CGH/FISH/GEP are already in use clinically or are being validated, further 
studies are necessary to develop more accurate, cost-effective, and practical methods to 
improve the accuracy of melanoma diagnosis.
(ii) Development of refined risk phenotypes could be improved by increasing the sensitivity 
and specificity of markers tailored to melanoma subtypes (iii) Additional standards useful to 
identify individuals with increased risk could include clinical or molecular markers 
indicating mutation load in skin as well as biomarkers for immune-competence and the state 
of the tumor stroma. (iv) Improved understanding of how melanomas evolve from precursor 
lesions will allow development of objective criteria for diagnosis based on the number and 
type of pathogenic mutations or perturbations in critical signaling pathways. Developing 
these objective standards will improve diagnosis of primary melanomas and enable 
classification of intermediate lesions, which cannot yet be accomplished using current 
methods (Table 1).
Melanoma screening efforts
The vast majority of primary melanomas emerge in skin where they can be readily detected 
without specialized instrumentation. Screening the general population for skin cancer has 
been controversial, as it is not yet clear whether this effort will lead to reduced deaths, 
particularly given the low mortality associated with the most common skin cancers (such as 
basal cell and squamous cell carcinomas). Thus, programs and policies regarding screening 
have focused on melanoma—the most deadly form of skin cancer.
A variety of screening programs have been proposed and carried out in the US and abroad. 
Critical for the success of these programs is the proper public education and the ability of 
general practitioners to refer patients directly to dermatologists for basic risk assessment. 
Lack of common protocols hampers the ability to compare screening efforts either between 
or within countries.
In 2009, the third US Preventive Services Task Force (USPSTF) evaluated worldwide 
evidence (through 2005) relevant to skin cancer screening by primary care physicians. They 
rated this screening as “Insufficient” to assess benefit or harm in early detection of 
melanoma and other skin cancers in the adult general population. No formal randomized and 
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controlled melanoma screening trials have been conducted worldwide (due to high cost and 
lack of feasibility). The USPSTF recently conducted a systematic review of worldwide 
evidence from January 1995 through June 2015, again assigning an “Insufficient” grade to 
melanoma screening by primary care physicians in the US in the Draft Recommendation. 
Nevertheless, the USPSTF continues to note the value of screening individuals at highest 
risk of fatal melanoma and recommends screening of these individuals, along with 
counseling of parents with young children, as well as young individuals aged 10–24 
regarding sun protection and effects of UV exposure on photoaging and skin cancer.
Slip-Slop-Slap (Slip on a shirt; Slop on the 30+ sunscreen; Slap on a hat) was an 
internationally recognized sun protection campaign in the 1980 in Australia. Later, this 
initiative was also noted in New Zealand, Canada and the UK. The education of the 
Australian population is a paradigm that can be followed, given the recognition, appreciation 
and measures undertaken for sun protection today. “Get Naked” is an example of a campaign 
spearheaded by the Melanoma Research Foundation over the past couple of years, which 
was largely conducted through social media or limited advertisements in public places. The 
simple public health recommendation that one should subject oneself to periodical self-
examination is expected to increase awareness and early detection of moles or lesions that 
can be evaluated by professionals soon after. The campaign has resulted in impressive social 
media attention, although it is too early to assess its impact and effectiveness. At present, 
there are several ongoing efforts nationwide designed to collect data on the impact of 
screening on melanoma detection, cost and survival.
Screening efforts recommendations—(i) large-scale, stand-alone media campaigns to 
encourage high-risk groups to undergo screening and support of state-based demonstration 
projects that combine media, provider reimbursement, and public education. (ii) Programs 
should emphasize collaboration with primary care clinicians to improve skin cancer triage 
and reduce morbidity and cost for all types of skin cancer. (iii) Studies to assess benefits of 
targeting those at highest risk of fatal melanoma, such as white men >50 years of age, should 
be conducted (Table 1).
Under reporting
Studies conducted in 2008 and 2009 raised concerns about melanoma under-reporting, with 
rates estimated in the range of 30–40%, while acknowledging that the overall magnitude of 
the problem remains unknown. A more recent study in the state of Arizona indicates that 
under-reporting rates might be as high as 70%. In the US, management of cancer data 
generally falls under the responsibility of state cancer registries, agencies that rely solely on 
providers submitting appropriate forms to them. Cancer incidence rates are calculated from 
data maintained by state cancer registries, and the accuracy of this information is highly 
dependent on the actual reporting of cancer cases from community sources, including 
physicians. The potential for under-reporting is especially high for melanoma, since it is 
frequently diagnosed and treated in outpatient settings and pathology may be read out of 
state.
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Single lesion assessment
Most single lesion evaluation is carried out through unaided skin examination and 
dermoscopic assessment. New technologies relevant to non-invasive melanoma diagnosis are 
emerging with the goal of increasing sensitivity and specificity of current practices. Among 
technologies that attempt to enhance and/or automate current practices are in vivo confocal 
microscopy, multispectral imaging, and electrical impedance. Challenges related to these 
approaches include the need for further validation to ensure diagnostic accuracy of these 
modalities, the demands of learning a new technology, variability among readers, lack of 
comparative trials between new technologies, and cost. In addition, dermatology practices 
seek to increase the efficiency of patient flow, and introduction of emerging technologies 
may slow this. Thus for successful adoption of new technologies it is necessary to identify 
barriers in implementation and implement systems that offer a clear advantage to current 
diagnostic approaches. In addition, many of these new technologies are unlikely to be widely 
available in the primary care setting, suggesting that they may enhance sensitivity and 
specificity of melanoma diagnosis on per-need basis.
Regional and total body imaging
Considering the rapidly emerging improvement and accessibility to digital imaging 
technologies, there is a need to effectively standardize the use of digital imaging in 
dermatology and other specialties when capturing regional and total body photographs. 
While several medical specialties have specific DICOM (Digital Imaging and 
Communication in Medicine) standards for digital communication, this is not the case for 
dermatology. An initiative established by the International Society for Digital Imaging of the 
Skin (ISDIS) seeks to standardize current practices for image capture, terminology, storage, 
and privacy issues surrounding digital imaging of patient skin (“International Skin Imaging 
Collaboration (ISIC): Melanoma Project”). The value of photographic digital imaging has 
been more consistently evaluated in settings where patients at high-risk for melanoma have 
undergone regional/total body imaging or when skin lesions have been monitored short term. 
Developing standardized parameters is critical as new systems capable of automated and 
semi-automated total body image capture are emerging.
Consumer-based early detection through mobile technologies
Mobile phones have revolutionized communication around the world, not only through 
voice-based communication but also through the development of phone-based social media 
(such as Twitter and Instagram) and development of healthcare-related mobile applications 
(apps). Phone-associated technologies, particularly the camera and the global positioning 
systems (GPS), enhance specific performance capabilities of apps. The app industry is 
rapidly entering the healthcare space, and because skin is so accessible, skin lesion 
photographs are commonly sent to physicians, who are being asked to evaluate these photos 
clinically. At this time, little data is available regarding the validity of such an approach. 
There are now over 100 melanoma detection apps available in app stores around the world, 
but none have yet been shown to demonstrate the capacity to diagnose melanoma.
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Need for increased specificity and healthcare cost implications
A critical consideration when assessing current melanoma screening practices relates to the 
number of procedures performed to diagnose the 76,100 cases of melanoma reported in the 
U.S. in 2015. Current estimates indicate that approximately twenty-five biopsies are 
performed for every diagnosis of melanoma rendered. By extension, this implies an estimate 
of 2,283,000 biopsies performed per year as part of current melanoma screening practices. 
However, under-reporting of melanoma is estimated to range from 40 to 70%. Assuming an 
average of 55% under-reporting rate across all states and a sustained biopsy rate of 25 
procedures for every melanoma diagnosed, an estimated 4,073,333 biopsies may be 
performed annually in the US to diagnose 169,111 melanomas.
An area of significant opportunity is detection of “amelanotic” melanoma. This tumor 
subclass was recently found associated with higher mortality than darkly-pigmented 
melanomas, probably due to diagnosis at a later (thicker) stage. Recent animal model-based 
studies suggest that in some amelanotic melanomas, dark pigment is replaced with 
pheomelanin. Imaging of pheomelanin may allow one to identify these more dangerous 
lesions.
Diagnosis technologies / reporting recommendations—(i) Modification of the 
reporting along with effective education of physicians for the need to report melanoma cases 
should increase the number of reported cases. (ii) Effectively standardize the use of digital 
imaging in dermatology and other specialties when capturing regional and total body 
photographs. (iii) Increase our ability to diagnose aggressive melanoma subtypes and to 
minimize morbidity associated with the comparatively larger number of unnecessary skin 
biopsies (Table 1).
Dormancy and Early Metastasis
It is well accepted that melanoma cells can be shed early from a primary tumor and remain 
silent or "dormant" as micrometastatic foci for periods ranging from under a year to decades. 
Clinically, dormancy describes the status of microscopic metastases prior to progression to 
overt cancer. Tumor dormancy is thought to depend on at least three elements: (1) cellular 
dormancy, in which tumor cells survive in a quiescent, slowly dividing state; (2) angiogenic 
dormancy, in which lack of vascularization holds growth of micrometastases in check and 
promotes programmed cell death, known as apoptosis; and/or (3) immune-mediated 
dormancy, where the immune system continues to limit the tumor population. Disruption of 
these processes can awaken dormant micrometastases and stimulate their expansion into 
overt metastases, leading to patient morbidity and mortality.
Maintenance of a dormant state likely requires intrinsic or "cell autonomous" factors and 
extrinsic microenvironmental cues. The latter can be derived from the vascular and 
lymphatic systems, the presence of inflammatory cells, or the activity of stromal and support 
cells. Relevant to the immune system, "immunoediting" may occur, a process in which most 
immunogenic tumor cells are eliminated, leaving a poorly immunogenic, dormant 
population. In cancer types other than melanoma, chemotherapies (a topic covered in 
another section of this report) have been shown to modulate either induction or escape from 
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dormancy. The adaptive immune system may also regulate tumor dormancy. Here, we view 
dormancy as an organ-based process and will discuss issues related to dormancy that must 
be considered when designing interventions.
Factors regulating dormancy
It is likely that complex mechanisms of crosstalk between cancer cells and their 
microenvironment and vice versa, initiate and establish tumor cell dormancy. In turn, 
mechanisms promoting cell survival and evasion of the immune system may be enhanced 
and potentially altered as a response to therapeutic agents. As a framework for future 
studies, the following stages of dormancy and mechanisms underlying them have been 
proposed: (i) Establishment of competency for a dormant state. Shed melanoma cells may be 
able to home directly to favorable metastatic sites, and many of those regions may favor 
tumor cell survival by creation of a pre-metastatic niche. However, like other tumor cells, 
melanoma cells may exploit reservoirs such as bone marrow as an intermediate site on the 
journey to a target organ. The possibility that dormancy can be also induced following 
exposure to a particular therapy cannot be excluded. (ii) Mechanisms governing long-term 
survival of tumor cells at metastatic sites. Cell survival mechanisms may be switched on 
either in solitary quiescent cells or in a small number or colony of cells. Such mechanisms 
may foster resistance to cytotoxic chemotherapy. (iii) Self-renewal mechanisms that 
maintain the capacity for tumorigenesis. These activities might allow a balance between cell 
proliferation and cell death. Both intrinsic and extrinsic (from the stroma, the vasculature, 
and/or the immune system) signals likely govern this balance. Activation/suppression 
mechanisms that affect aggressive outgrowth. A combination of intrinsic and extrinsic 
factors, including microenvironment, angiogenesis and immune-surveillance are expected to 
impact the nature of outgrowth.
Noteworthy issues relevant to melanoma dormancy
Our current understanding allows us to define similarities/differences between dormancy in 
melanoma and other tumor types. Growing evidence supports the influences of melanoma 
cell plasticity and stem-like properties on dormancy, yet, precise factors that underlie the 
switch to dormant cells are not known. Likewise, the relationship between melanoma 
dormancy and physiological stem cell dormancy is an important aspect that requires further 
study.
In recognizing the nature and significance of melanoma dormancy, it is conceivable that "re-
awakening" dormant cells could make them susceptible to immunological and/or targeted 
drug therapy. In this context, the role of the premetastatic niche in establishing or awakening 
dormancy is an important area to explore. Lastly, one cannot ignore the importance of the 
bone marrow as a nurturing environment for the dormant melanoma cells. At present, the 
molecular analysis of melanoma dormancy lags significantly behind that of breast and 
prostate cancers. Research directed at filling this gap is required.
Clinical considerations in assessing melanoma dormancy
With high cure rate in patients subjected to surgical therapy, one may question the 
significance of dormancy in such cases. Notably, we do not know whether patients that were 
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cured lacked dormant melanoma cells. Thus, with our current understanding it will be 
important to assess dormancy during all three phases of clinical investigation: (i) detection/
diagnosis, (ii) prediction/prognosis, and (iii) treatment. A better understanding of tumor 
dormancy at these points in time would allow us to block awakening mechanisms. It is 
anticipated that tumor dormancy will be most efficiently targeted in patients with earlier 
stage disease, provided that effective treatment regimens are available. Thus, an analysis of 
whether current regimens are effective against dormant tumor cells is warranted. New 
approaches to adjuvant therapy, either pre or post surgical removal of the primary tumor, 
also need to be considered. Finally, there is a critical need to identify blood-based 
biomarkers and novel imaging strategies that may indicate the status of a patient’s dormant 
tumor cells, as well as novel imaging strategies to detect them.
Development and exploitation of models of melanoma dormancy
It is evident that animal models can significantly complement analysis of clinical samples by 
providing a platform to define basic mechanisms underpinning tumor initiation, as well as to 
serve for pharmacological screens. However, effective models of tumor dormancy are rare 
and must be established for physiologically-relevant studies. Based on the already well-
appreciated heterogeneous and plastic nature of melanoma, dormant cells in this disease will 
likely have inherent properties that require tailored genetic engineering.
The mouse is the most well-characterized system available. Cell lines that exhibit dormant 
behavior when engrafted into mice have been described, and one mouse melanoma 
dormancy model has been established in the context of constitutive RET activation. 
However, zebrafish models may offer a complementary alternative. In either case, care must 
be applied to develop models most representative of conditions underlying dormancy of 
human tumor cells. More challenging is the development of cellular models (namely, 
genetically-matched cell lines with a distinct potential for dormancy) that recapitulate at 
least some aspects of the physiology of human melanoma. Such systems, which have been 
described in breast cancer, would represent a tremendous advantage in understanding 
mechanisms associated with awakening of dormant melanoma cells.
Characteristics and needs of tumor dormancy models include—(i) Tumor cell 
dissemination to organs that are the most frequent targets of human melanoma metastasis; 
tumor-microenvironmental interaction; (ii) Methodology capable of identifying proliferative 
versus silent cells or cell clusters in vivo; (iii) Immunocompetence to assess immune 
contributions (e.g. inflammatory cells) and the possibility to evaluate antigen-specific 
responses; (iv) Capability to evaluate genotype-specific effects on dormancy; (v) Ability to 
evaluate the microenvironment of micrometastases, including ECM, target organ cells, 
endothelial cells, pericytes, inflammatory cells, and cancer-associated fibroblasts; (vi) 
Ability to study effects of aging on dormancy; (vii) Heterogeneity of micrometastases and 
their primary melanoma of origin; (viii) Ability to employ an on/off switch from dormant 
micro- to macro-metastases; (ix) Ability for live imaging by non-invasive methods or by 
intravital microscopy; (x) Capability to conduct whole-body imaging of angiogenesis and 
lymphangiogenesis (e.g. by exploiting VEGFR3-driven luciferase knock-in models); (xi) 
Methodology to image metastatic and premetastatic niches; (xii) Ability to test how 
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mutational burden affects dormancy; (xiii) Ability to detect conversion from dormant to 
growing cells in live animals.
Dormancy model tools and approaches currently available and adaptable 
include—(i) GEM models. Use of these models could be coupled with surgical removal of 
the primary melanoma. Incorporation of Cre-based fluorescent reporters would add value to 
this model. (ii) Grafted models. These include orthotopic subcutaneous implants for 
cutaneous melanoma models, with and without surgery. Other implantation strategies can 
include left ventricle or tail vein injection. For uveal melanoma, injections into the eye uveal 
tract are feasible and may be pursued as an anatomically-relevant setting. Although, it would 
certainly be more advantageous to employ an immunocompetent model system, human 
melanoma cells and tissue can be grafted into immunocompromised host mice. Future 
availability of host mice with humanized immune systems will greatly enhance the value of 
this approach. Availability of appropriate cellular models that mimic genetics of the human 
disease would also add value to this general approach. (iii) Genetic engineering. This will 
include CRISPR-based gene editing as well as transposon-based mutagenesis. (iv) 
Multidimensional “omics” analyses. These technologies can be focused on isolated single 
cells and include analysis of RNA, DNA, epigenetic changes and metabolism. (v) Imaging 
modalities. Multiple modalities are currently available, including bioluminescent imaging, 
fluorescent stereomicroscopy, 2-photon microscopy, light sheet microscopy, micron-sized 
nanoparticle-based imaging, and quantitative histological imaging. (vi) Reporter tools. 
Numerous reporters are available that can distinguish between the vasculature, macrophages, 
fibroblasts, lymphocytes, and other cells or tissues. Importantly, more complex reporter 
systems are already available that can separate proliferating from quiescent/dormant cells in 
vivo. (vii) Monitoring. Development and incorporation of better tools for assessing 
dormancy in clinical trial design, such as measuring and profiling CTCs, circulating tumor 
DNA and exosomes, assessing bone marrow for dormant cells are important. The ability to 
simultaneously identify and isolate dormant and proliferating populations from several 
metastatic sites is also of relevance for both cutaneous and uveal melanoma, and 
development of improved tools is a priority.
Targeting dormancy
Targeting dormant cells poses significant challenges, as one needs to consider the partial 
elimination of some while awakening others. Their select targeting is of equal challenge 
given their distinct state of proliferation and metabolism. Here, immunotherapy could be 
useful if dormant cells express antigens recognized by the immune system; however, a 
dedifferentiated state may mask dormant cells. Dormant cells may upregulate several cell 
survival pathways that can also oppose drug response. Moreover, the wiring of pro-
tumorigenic pathways may be distinct depending on the specific environment 
(“conditioning”) of the pre-metastatic niche. Therefore, a better understanding is needed on 
how available chemo- or immuno-therapies impact either establishment or awakening of 
dormant cells. The following are possible strategic approaches: (i) Prevention. The goal of 
this approach is to keep cells in an indefinite dormant (G0) state. In this context, it is of 
relevance to note patient-related compliance issues, which drops if treatments extend beyond 
6 months. Therapy would need to be safe and tolerated over years of administration. 
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Differentiation therapy may also be considered in an effort to induce a permanent G0 state 
for dormant cells. (ii) Awaken and target dormant cells. This approach requires identifying 
pathways underlying awakening to push quiescent cells out of dormancy. Those cells would 
then be targeted and killed using conventional anti-proliferation therapy. This approach is 
risky as it could result in generation of highly aggressive cells, hence complicating clinical 
tests due to ethical considerations. (iii) Eradicate all dormant cells. This approach would 
require identification of single or combination-based therapies with a broad spectrum of 
action. Some approaches to be considered include: (iv) Target survival pathways that sustain 
dormant cells; (v) Target embryonic pathways that maintain the dormant state (vii) Target 
the “dormancy niche” by altering cell adhesion and/or cell to cell communication; (viii) 
Trigger immunogenic protein expression in dormant cells, possibly by inducing presentation 
of differentiation antigens; (ix) Eradicate dormant cells using monoclonal antibodies 
specific/selective for tumor antigens coupled to toxins, a-particle emitters or other toxic 
substances; (x) Implement adjuvant therapies to attack dormant cells early, perhaps at 
primary tumor resection; (xi) Extend the length of treatment, depending on drug toxicity, 
which may sustain dormancy, quiescence and or differentiation.
How to best apply translational research to assess tumor dormancy in patients?
Tumor dormancy can be studied in retrospective and prospective cohorts of patients. These 
can include patients with thin melanomas and positive sentinel nodes and poor clinical 
outcome, versus those with similar histopathological manifestations but a positive prognosis. 
Cohorts from randomized clinical trials are of highest value. Such specimens are already 
available though highly dedicated clinical teams and are needed to identify and annotate 
cohorts of interest. Importantly, this effort will require sharing of samples/datasets (ideally 
through controlled repositories) to foster collaboration among multiple investigators and 
sites to increase sample size and statistical power. As tumor material may be limited, it will 
be important to prioritize samples (primary lesions, metastases, blood) and time-points to be 
analyzed. Similarly, efforts should be dedicated to “downstream analyses”, including 
molecular and immune studies of tumor and blood samples. We also need to define 
additional potential contributors (e.g. germline signatures of susceptibility/influence of the 
gut microbiome) to direct experimentation and mathematical modeling. These questions 
should be addressed by collaborative approaches and coordination with multiple 
stakeholders, including, policy makers and funding agencies. Specific funding calls will be 
needed to ensure productive and long-lasting interactions. As we move forward, it will be 
important to perform these studies via a “co-clinical trials” approach—with parallel studies 
in man and mouse for trans-species cross-validation of mechanisms and insights gained.
Dormancy Recommendations—(i) Assess early metastasis and tumor dormancy in 
cohorts of patients with melanoma to better understand activities leading to disease 
progression. (ii) Develop biologically relevant models of metastatic dormancy in which to 
conduct mechanistic and functional analyses. (iii) Integrate Data from preclinical studies to 
inform clinical approaches. (iv) Determine what constitutes competency for a dormant state 
and what governs long-term survival of dormant cells at metastatic sites. (v) Identify 
mechanisms that maintain dormant cell capacity for tumorigenesis (vi) Define activation/
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suppression mechanisms that influence aggressive outgrowth of dormant cells. (vii) 
Determine whether dormant cells should be awakened or maintained dormant (Table 1).
Therapy: Status, Challenges, and Opportunities
Advances over the past decade have identified genetic changes that allow stratification of 
melanomas into distinct groups. Among those, tumors harboring BRAF or NRAS mutations 
are most prevalent. Other groups include melanomas with genetic changes in the NF1, KIT 
or RAC1 genes. The genomic landscape of melanoma is also defined by epigenetic changes 
in complexes of proteins that interact with DNA to regulate gene expression. Some of the 
latter parallel genetic alterations, while others reflect a cellular response to environmental 
stimuli that drive cells to adapt to harsh conditions (such as lack of nutrients or 
chemotherapeutic drugs). While the analysis of somatic mutations has generally focused on 
their effects on protein functions, there is growing interest in their potential immunological 
effects (e.g. neoantigens are potent immunogens).
In parallel to an improved understanding of the genetic basis of this disease, the treatment of 
patients with metastatic melanoma has undergone a paradigm shift in the last 5 years. Prior 
to 2011, only two therapies (dacarbazine and high-dose bolus interleukin-2 [IL2]) were 
approved in the US to treat these individuals. Both achieved clinical responses in <15% of 
patients, but neither demonstrated significant impact on patient survival in a randomized 
trial. Thus, until very recently the only real option for patients with metastatic melanoma 
was to participate in a clinical trial of an experimental drug or treatment. However, after a 
prolonged period of failed trials, the US FDA granted regulatory approval to 10 new 
therapeutic regimens for patients with metastatic melanoma between 2011 and 2015, events 
that were both unprecedented and exciting. Melanoma patients and their physicians now 
have a plethora of therapeutic options at their disposal.
Despite major progress, the need for high-quality clinical and translational research remains. 
Little is known about how best to match patients to therapies with the greatest probability of 
promoting long-term disease control, and overcoming resistance to existing therapies 
remains a pressing need. Thus, there is now a critical opportunity to build on the growing 
foundation of knowledge to translate predictive biomarkers into diagnostic tests, to develop 
tools to discern mechanisms of resistance, and to rapidly develop next generation therapies.
Targeted therapies
The development of approved targeted therapies has been driven by significant advances in 
understanding the diverse molecular mechanisms of melanomagenesis. In particular, 
availability of therapies for patients with BRAFV600 mutations, which occur in ~45% of 
non-acral cutaneous melanomas, has been promising but also identified key challenges that 
must be overcome to maximize long-term clinical benefits of this strategy. Combined 
treatment with BRAF and MEK inhibitors as a therapeutic approach achieves RECIST 
(response evaluation criteria in solid tumors) responses in ~70% of patients with BRAFV600 
mutations and disease control in virtually all patients. However, most treated patients will 
eventually exhibit disease progression due to a constellation of resistance mechanisms 
emerging from tumor heterogeneity within an individual patient. To date, no targeted 
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therapies have demonstrated significant clinical efficacy in patients whose disease 
progresses following BRAF/MEK inhibition, thus driving an active area of research.
In addition to new mutations, epigenetic factors and tumor interaction with the 
microenvironment likely play roles in drug resistance, activities that present diagnostic 
challenges but also new therapeutic avenues. Diagnosis in particular is complicated by the 
heterogeneity of resistance. Thus, while much can be learned from biopsies, more global 
diagnostic tools (such as markers detectable in blood or molecular imaging) are needed to 
stratify “types” of resistant patients in order to develop rational, effective approaches. Patient 
outcomes may also be improved by interrogation of targeted therapy dosing strategies, 
including intermittent approaches, which delay resistance, or by higher dosing in terms of 
combination therapies. Higher dosing may be particularly relevant to central nervous system 
(CNS) metastases, which remain a significant therapeutic challenge. There is also an unmet 
need to identify markers to identify patients who will achieve a more durable benefit from 
BRAF and BRAF/MEK inhibition, a phenomenon known to occur in 10–20% of BRAFi-
treated patients and up to 30% of BRAF/MEK-inhibitor-treated patients.
Finally, it is also critical to identify effective strategies to treat metastatic melanoma in 
patients lacking BRAFV600 mutations. In depth studies of cutaneous melanomas have 
identified several additional potentially targetable genes and pathways. The lessons learned 
from the still-evolving treatment of patients with BRAFV600 mutations should facilitate 
progress in developing therapies aimed at patients who lack them, most of whose 
melanomas harbor activating NRAS or inactivating NF1 mutations. Both alterations perturb 
RAS signaling; thus a key question, which is also relevant to multiple other cancers, is 
whether to directly target RAS or consider targeting of effectors of RAS signaling, such as 
RAF protein kinases or phosphatidylinositide (PI)-3’ kinases. Initial molecular profiling 
studies also show that non-cutaneous melanoma subtypes have distinct biologic properties. 
This is particularly true of uveal melanoma, which is characterized by one of the lowest 
mutation rates of all solid tumors and by a distinct set of somatic alterations. There are 
currently no effective therapies available to treat this condition, presenting both a need and 
an opportunity.
Immunotherapy
Immuno therapy posits that one does not need to treat tumor cells but rather prime a 
patient’s immune system to more efficiently attack the patient’s tumor. This approach has 
revolutionized melanoma therapy and resulted in unprecedented rates of long-term disease 
control and survival in patients with metastatic disease. However, multiple challenges and 
opportunities remain to optimize this therapeutic approach.
The clinical experience with high doses of the cytokine IL2 provided the proof-of-concept 
that immunotherapy can result in long-term disease control and survival in metastatic 
melanoma patients, albeit only in a very small percentage of patients and with very high 
toxicity in all treated patients. However, the clinical development of immune checkpoint 
inhibitor therapy has made such outcomes a reality for an increasing number of patients. For 
example, long-term follow-up with ipilimumab (Ipi), which targets CTLA4, indicate that 
~20% of patients survive at least 3 years after initial treatment, with current data suggesting 
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that few patients relapse and die after that benchmark. This benefit is balanced by the fact 
that Ipi treatment has a low clinical response rate (~10%), a slow onset of action, and a 
significant rate (up to 25%) of autoimmune toxicity. The approved single-agent anti-PD1 
antibodies nivolumab (Nivo) and pembrolizumab (Pembro) achieve clinical responses in 30 
to 45% of patients, including individuals who have failed Ipi either due to disease 
progression or drug toxicity. Nivo and Pembro are also associated with much lower rates 
(<10%) of autoimmune toxicity than Ipi. Long-term survival data is still pending for these 
agents, but many clinical responses to PD1 antibodies appear to last for at least the duration 
of active treatment thus far (2 years). Randomized trials with Nivo and Pembro 
demonstrated significant improvements in safety, response rates, and in overall survival 
compared to Ipi. It remains to be determined which patient subpopulations will derive long-
term benefit from each therapy.
Questions remain about how to further improve the efficacy of these agents. Current 
evaluation of combined Ipi + Nivo treatment suggests significantly increased response rates, 
with 50 to 60% of patients responding positively. However, the regimen is also characterized 
by a high rate of autoimmune toxicity. Clinical trials are under way to test other 
combinatorial approaches, with success defined not only as improved efficacy but safety and 
tolerability. Complementary efforts are aimed at understanding resistance to immunotherapy. 
Initial findings suggest that PD1-resistant melanomas are characterized by markedly lower 
T-cell infiltration and by lower tumor inflammation, revealing a potential early 
pharmacodynamic endpoint useful to assess in clinical trials with new therapies and 
combinations. Molecular studies also show that melanomas with a relatively low mutation 
burden are less likely to respond to Ipi, although this finding has not yet prevented clinicians 
from treating patients with this therapy. Molecular analyses identified other oncogenic and 
targetable pathways in tumor cells that may promote resistance to immune recognition, 
infiltration, and tumor killing, and trials combining MAPK inhibitors with immunotherapies 
are under way. Finally, there are many other key regulatory molecules that have been 
identified on T cells. These molecules may have roles not only as therapeutic agents, but 
could potentially also be biomarkers of efficacy, resistance, and/or toxicity.
Opportunities
Clinical therapy for melanoma is ripe with challenges that, if met, could further improve 
disease outcomes. One low-hanging fruit is the need for clinical interrogation of alternative 
dosing strategies for currently available agents. For targeted therapies, preclinical studies 
support the idea that intermittent strategies may slow or prevent drug resistance. For immune 
therapies, the optimal frequency and duration of therapies is unclear. Testing of alternative 
dosing strategies could have safety benefits and, in fact, may be necessary if significantly 
higher-order combination regimens are needed to maximize long-lasting disease remissions. 
Fiscal benefit could also drive prioritization of treatment strategies in an increasingly cost-
confined healthcare system. Assessment of dosing strategies would clearly benefit greatly 
from new markers that accurately predict clinical benefit early in treatment.
Dramatic progress seen in treating patients with distant metastases suggests that patients 
with regional disease or even high-risk localized melanoma could experience similar 
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benefits. In particular, the development of reagents with high response and disease control 
rates with minimal toxicity presents an opportunity to safely explore neoadjuvant 
approaches for patients with surgically resectable disease. Neoadjuvant treatment may 
provide significant clinical benefit not only by reducing the morbidity and/or complexity of 
surgical procedures, but also by providing information to guide whether a therapy is 
beneficial and should be continued in the adjuvant setting. A neoadjuvant approach also 
provides a chance to acquire high-quality biospecimens to analyze resistance mechanisms, 
which remains challenging in stage IV patients. Neoadjuvant evaluation of early-stage 
investigational agents could also rapidly evaluate whether that reagent achieved significant 
target inhibition at clinically-tolerated doses. Finally, the demonstration of long-term clinical 
benefit from short-term neoadjuvant treatments may also establish a more efficient paradigm 
to evaluate and potentially approve new therapies.
In contrast to recent therapeutic advances, the development of molecular and/or immune 
diagnostics to guide clinical care remains largely unrealized. While many research efforts 
are underway to identify individuals with stage IV disease who are most likely to benefit—
or not—from current systemic therapies, there is a strong rationale to also identify patients at 
greatest risk of side effects. Improved biomarkers will also be critical for the rational use of 
systemic therapies in patients with earlier stage disease, particularly given the high cost of 
most new therapies. These studies should be complemented by efforts to improve risk 
models for earlier stages of disease and to guide appropriate selection of patients in which 
the risks and costs of aggressive treatment are justifiable.
Heterogeneity within and between tumors presents a significant challenge for overcoming 
resistance to therapies. While currently available collections of tumor biopsies remain 
essential to research, the development of non-invasive biomarker strategies would be 
clinically beneficial. For example, blood-based biomarkers could be a powerful adjunct to 
current surveillance strategies for patients with early stage disease. For patients receiving 
systemic therapies, sensitive blood-based response markers could rapidly and rationally 
guide treatment decisions and expedite evaluation of new strategies. In addition to blood-
based markers, new imaging approaches capable of assessing key disease outcomes, such as 
immune cell infiltration, could also have tremendous clinical impact.
Progress seen in clinical trials and regulatory approvals largely reflects the experience in 
non-acral cutaneous melanoma patients without significant co-morbidities. There is a need 
for increased investigation relevant to populations previously excluded or under-represented 
in landmark trials. For example, clinical trials in patients with significant co-morbidities, 
including autoimmune disease and CNS involvement, will help guide treatment of real-
world patient populations. The distinct molecular biology of non-cutaneous melanoma 
subtypes, including mucosal and uveal melanoma, also provide a rationale for focused 
investigations in these populations.
With the growing understanding of melanoma cell biology, the tumor microenvironment, 
and the role/regulation of the immune system in cancer control, a large number of new and 
exciting drugs are now at various stages of clinical development for this disease. Yet, with 
several drugs that improve survival (but cure few) already widely available in clinical 
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practice, determining and validating surrogate clinical endpoints for long-term efficacy is an 
urgent need to optimize the design and conduct of clinical trials. Such improvements will 
ensure that drugs with significant efficacy will be available to patients in a timely manner.
Therapy Recommendations—(i) Develop experimental models to explore novel 
immunotherapy and signaling based therapy approaches that take into account the genetic 
and biologic signatures of the disease. (ii) Identify mechanistic basis of intra-tumoral 
heterogeneity and develop strategies to overcome this clinical obstacle. (iii) Identify and 
validate biomarkers to select patient sub-groups for targeted therapies. (iv) Identify 
biomarkers for selection of 2nd line target therapies in for treatment-resistant tumors. (v) 
Improve efficacy, safety and tolerability of the current generation of checkpoint inhibitors 
and develop biomarkers for more precise selection of therapies.
The path forward
There remains a critical need to encourage participation in clinical trials in the melanoma 
patient community. Despite many regulatory approvals over the last 5 years, there remains 
an unacceptably high rate of treatment failure and death from this disease. Melanoma 
researchers must partner with patient support and advocacy organizations to communicate 
this message, and find ways to optimize the ease and safety of participation in clinical trials. 
This message must also be communicated effectively to funding agencies to ensure 
continued progress. Progress also critically depends upon collaboration and cooperation with 
pharmaceutical companies, particularly in designing and supporting innovative trials that 
may provide new insights.
Ample evidence now supports the idea that there is significant overlap between the 
regulation of oncogenic signaling and the anti-tumor immune response, and that both 
determine the efficacy of (or promote resistance to) targeted and immune therapies. In the 
future, preclinical models must be developed that allow concurrent evaluation of both 
molecular and immune factors and include dedicated analysis of both in experimental 
designs. Clinically, there is a need to systematically evaluate both the optimal sequence of 
and proper combination of targeted and immune therapies to identify safe and effective 
strategies for patients. It is likely that subsets of patients will benefit differentially from these 
approaches, and thus there is a critical need for infrastructure to collect and annotate high-
quality biospecimens. Furthermore, such studies should incorporate analyses of both tumor 
and host factors, such as germline polymorphisms and the patients’ microbiome.
In addition to our appreciation of drug combinations, we are also in an era that requires 
multi-disciplinary clinical care and expertise. For example, new opportunities for 
neoadjuvant therapy will be most impactful if there is close collaboration between medical 
oncologists, surgical oncologists, and pathologists. There are likewise opportunities for 
collaborative investigations that include radiation therapy and other interventional 
modalities; these are just beginning to be realized but will likely expand significantly. 
Importantly, the growing list of therapeutic options across the melanoma continuum requires 
multidisciplinary input in patient care and in design of clinical research. Similarly, close 
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collaboration and communication between clinical and laboratory investigators are essential 
to expedite progress in the field and provide a strong rationale for new clinical studies.
Relevant to development of future treatment strategies, there is interest in cellular machines 
that normally maintain cellular homeostasis but are subverted in tumor cells to promote 
survival. Thus far, these approaches, which are equally relevant to melanoma, focus on five 
complex biochemical processes: (1) the initiation complex for protein translation; (2) the 
unfolded protein response (UPR), including the cellular response to misfolded proteins (also 
part of the ER stress response); (3) the spliceosome, which functions in mRNA splicing and 
hence gives rise to novel proteins, some of which may underlie cancer; (4) the apoptotic 
machinery, which is has already been shown to regulate the responsiveness of melanomas to 
targeted therapy; and (5) the machinery of autophagy, which may regulate the response of 
melanoma cells to targeted blockade of pro-tumorigenic signal transduction pathways. 
Ongoing studies should define activities of these complexes in drug resistance or metastasis 
and begin to identify reagents to target them.
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Table 1
The 2016 Road map for Melanoma: Challenges and Opportunities
Prevention
• Define challenges and opportunities in context of environmental exposure and individual 
(epi)genetic makeup
• Incorporate genetic, epigenetic, dietary, behavior and sun exposure data in design of clinical 
evaluations
• Define the impact of UV wavelengths / filters and their optimal uses (sunscreens)
• Understand cognitive process underlying sun exposure behavior
• Improve communication with and education of “at risk” individuals
• Understand and develop means for possible control of melanins / pigmentation
• Define the microbiome: possible impact on the immune system and melanoma development.
Early detection / Diagnosis
• Develop better tools to identify melanoma earlier
• Develop methods to identify precursor lesions at high risk for progression to melanoma
• Develop melanoma subtype-specific early detection algorithms (à la ABCD) for patients and 
providers
• Develop melanoma subtype-specific staging criteria for improved prognostication, and melanoma 
subtype-specific risk pheno- and genotypes
• Establish more accurate cost effective methods for diagnosis
• Improve reporting and standardize use of imaging technologies
• Promote media campaigns to educate the public for protection and screening
Dormancy / metastasis
• Develop better tools to detect and prevent metastasis
• Determine what constitutes competency for a dormant state and what governs long-term survival of 
dormant cells at metastatic sites
• Identify mechanisms that maintain dormant cell capacity for tumorigenesis
• Establish genetic models of tumor dormancy to evaluate mechanisms underlying the establishment 
and reawakening of dormant cells
• Determine whether dormant cells should be awakened or maintained dormant as part of defined 
therapy
• Study dormancy in retrospective and prospective cohorts of patient specimens
• Monitor dormancy in clinical trial setting, using markers and driver genes identified in experimental 
genetic models
Therapy / resistance
• Identify mechanisms of resistance and therapeutic modalities to overcome it
• Define mechanisms underlying- and strategies to overcome- intra-tumoral heterogeneity
• Develop experimental models to explore novel immunotherapy and signaling therapy approaches 
that take into account the genetic and biologic signatures of the disease
• Identify biomarkers for selection of 2nd line target therapies for treatment of resistant tumors
• Improve efficacy, safety and tolerability of checkpoint inhibitors and develop biomarkers for more 
precise selection of therapies
• Define the mode and sequence of therapy administration when combinations are used
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• Identify new sub-groups for targeted therapies
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